ArticleCancer discovery2021
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 253 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
253citing papers in PubMed, 2 pooled it
25.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
253 citing papers in PubMed, 2 syntheses or guidelines pooled it, 453 citations in OpenAlex.
- The relationship between the network of non-coding RNAs-molecular targets and N6-methyladenosine modification in tumors of urinary system.Cell death & disease · 2024Pooled it
- COVPRIG robustly predicts the overall survival of IDH wild-type glioblastoma and highlights METTL1Journal of translational medicine · 2023Pooled it
- Article
- LAMTOR5 drives glioblastoma progression via activation of the HOXC9/YTHDF2 positive feedback loop.The Journal of biological chemistry · 2026Article
- FMRP promotes gastric cancer progression via mJournal of translational medicine · 2026Article
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- RModBlock antisense oligonucleotides as a universal tool for precise and efficient inhibition of RNA modifications.Nature biomedical engineering · 2026Article
- GDPPH1 induces cell cycle arrest by downregulation of CDK4/Cyclin D1 via the mCell death & disease · 2026Article
- AKAP1 enhances glycogen accumulation and hepatocarcinogenesis through YTHDF2-mediated G6PC mRNA decay.Signal transduction and targeted therapy · 2026Article
- Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026Review
- Integrative Analysis and Experimental Validation Identify Potential m6A-Related Biomarkers for Osteoporosis.Genes · 2026Article
- Targeting Tumour Microtubes to Disrupt Glioma Networks.Research square · 2026Article
- Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.Annals of hematology · 2026Review
- RNA N6-methyladenosine (m6A) regulates cell cycle progression in diffuse midline glioma (DMG) and confers sensitivity to FTO inhibition.Cell death & disease · 2026Article
- Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.Translational andrology and urology · 2026Article
- Mechanisms and therapeutic potential of YTHDF readers: Linking epitranscriptomics to cancer.Journal of pharmaceutical analysis · 2026Review
- NNature reviews. Cancer · 2026Review
- NAT10 triggers colorectal cancer progression via promoting PPAN-regulated DNA damage repair.Oncogene · 2026Article
- Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.Cancer cell · 2026Review
- Leveraging the germ layer development patterns to predict prognosis and identify MEST as a novel therapeutic target in glioma.Cancer cell international · 2026Article
193 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Deobrat DixitDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Briana C PragerDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Ryan C GimpleDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-7189-3243
Hui Xian PohDepartment of Pharmacology, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-4286-9217
Yang WangTumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.ORCID 0000-0002-5993-9368
Qiulian WuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Zhixin QiuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0001-7103-8004
Reilly L KidwellDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Leo J Y KimDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-1790-9136
Qi XieDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Kristoffer Vitting-SeerupBrain Tumor Biology Group, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0002-6450-0608
Shruti BhargavaDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Zhen DongDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Li JiangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.
Zhe ZhuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-5385-948X
Petra HamerlikBrain Tumor Biology Group, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0002-5856-0161
Samie R JaffreyDepartment of Pharmacology, Weill Cornell Medicine, New York, New York.
Jing Crystal ZhaoTumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. drjeremyrich@gmail.com xiuxingwang81@163.com czhao@sbpdiscovery.org.ORCID 0000-0002-0446-0456
Xiuxing WangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California. drjeremyrich@gmail.com xiuxingwang81@163.com czhao@sbpdiscovery.org.ORCID 0000-0002-5993-9368
Jeremy N RichDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, California. drjeremyrich@gmail.com xiuxingwang81@163.com czhao@sbpdiscovery.org.
University of California San Diego · USCornell University · USDanish Cancer Society · DKDiscovery Institute · USUniversity of Pittsburgh · US
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MMechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0MDynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4MTargeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)R01CA238662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAY, STEVE A, RICH, JEREMY N · 2020 to 2024
$2.8MTargeting Ferritin in GlioblastomaR01CA169117 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI BAO, SHIDENG, CONNOR, JAMES ROBERT · 2013 to 2017
$2.7MMetabolism Informs Intertumoral & Intratumoral HeterogeneityR01NS087913 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NAKANO, ICHIRO, RICH, JEREMY N · 2014 to 2018
$2.0MTargeting Brain Tumor Stem Cells Through Novel Therapeutic CombinationsR01CA154130 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI RICH, JEREMY N · 2010 to 2014
$1.9MRole of post-transcriptional RNA methylation in the regulation of RNA activityR01GM110090 · NIGMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ZHAO, CRYSTAL · 2015 to 2019
$1.9MDual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)R01NS103434 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2017 to 2021
$1.7MEnergy Stress in Brain Tumor Initiating Stem CellsR01NS089272 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICH, JEREMY N · 2014 to 2018
$1.7MControl of gene expression in neural stem cells by crosstalk between messenger RNA methylation and histone modificationR01GM132292 · NIGMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI BAGCHI, ANINDYA · 2019 to 2022
$1.6MNCI NIH HHS F30 CA203101NCI NIH HHS F30 CA217065NCI NIH HHS F30 CA217066NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA154130NCI NIH HHS R01 CA169117NCI NIH HHS R01 CA171652NCI NIH HHS R01 CA186702NCI NIH HHS R01 CA238662NCI NIH HHS R35 CA197718NIGMS NIH HHS R01 GM110090NIGMS NIH HHS R01 GM132292NIGMS NIH HHS T32 GM007250NINDS NIH HHS R01 NS087913NINDS NIH HHS R01 NS089272NINDS NIH HHS R01 NS103434
Abstract
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSC). Here, we interrogated
Indexed as
Brain NeoplasmsGlioblastomaHumansNeoplastic Stem CellsRNA-Binding ProteinsRNA, MessengerRNA-Binding ProteinsRNA, MessengerYTHDF2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.